Krebs Biochemicals & Industries Ltd.
•Add ratio to table
ABOUT
AI Sector View
AI GENERATEDHealthcare
This stance relies on proxies and positioning because no direct pharma-export or healthcare operating series exists in the dataset. The depreciated currency at 95.23 (Sep/26) can support export earnings, inflation at 4.45% (Jul/26) is manageable for a defensive sector, and consumer spending remains large at INR 44743 billion (Jun/26). Strong FPI inflow of INR 10620 crore over 3 months to 2026-08-31 from INR -11381 crore in the prior 3 months adds a real sector-specific tailwind, but confidence stays capped because the fundamental drivers are indirect proxies.
PROS
- Company is almost debt free
- Operating margins have improved to -34.7% from -55.0%
- Working capital cycle has improved - days down from -321 to -786
CONS
- Net worth is negative - accumulated losses have eroded equity
- Company is loss-making at the operating / net level
- Operating cash flow has been negative in recent years
- Company has a low return on capital employed of -25.8%
- Company has a low return on equity of 0.0% over last 3 years
- Interest coverage is weak at -3.6x - earnings barely cover interest
* The pros and cons are machine generated based on quantitative rules.
Peer comparison
| Name | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | 1899.00 | 37.67 | 455633.71 | 0.84 | 2901.23 | 26.53 | 15299.88 | 10.98 | 19.11 | 28.81 |
| DIVISLAB | 9100.00 | 82.59 | 241576.41 | 0.33 | 902.00 | 65.50 | 3080.00 | 27.80 | 21.51 | 40.75 |
| TORNTPHARM | 4850.00 | 84.58 | 184478.41 | 0.78 | 566.00 | 3.28 | 4921.00 | 57.32 | 19.27 | 33.81 |
| CIPLA | 1385.00 | 33.19 | 111888.39 | 0.94 | 785.55 | -39.18 | 7119.28 | 4.13 | 16.00 | 16.73 |
| ZYDUSLIFE | 1121.00 | 24.78 | 111820.18 | 0.09 | 990.20 | -34.90 | 8017.00 | 23.97 | 21.39 | 24.54 |
| LAURUSLABS | 1840.00 | 90.93 | 99417.45 | 0.11 | 362.07 | 123.94 | 2026.31 | 29.10 | 18.20 | 31.50 |
| LUPIN | 2111.00 | 17.46 | 96528.82 | 0.85 | 1416.98 | 16.01 | 8276.89 | 34.28 | 28.86 | 29.59 |
| DRREDDY | 1154.00 | 29.89 | 96322.06 | 0.69 | 435.60 | -69.10 | 8099.80 | -5.21 | 13.75 | 10.63 |
| MANKIND | 2328.55 | 47.09 | 96179.61 | 0.04 | 574.09 | 29.12 | 4030.59 | 12.89 | 13.24 | 26.30 |
| AUROPHARMA | 1653.30 | 25.62 | 95127.23 | 0.24 | 1032.03 | 25.22 | 9150.35 | 17.44 | 12.76 | 20.54 |
| GLENMARK | 2427.00 | 38.10 | 68495.93 | 0.10 | 482.83 | 927.88 | 4018.48 | 31.35 | 20.35 | 20.03 |
| KREBSBIO | 56.00 | 0.00 | 120.74 | 0.00 | -2.49 | 53.29 | 6.98 | 27.45 | -29.92 | 11.84 |
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 11 | 15 | 13 | 12 | 13 | 13 | 11 | 6 | 5 | 4 | 7 | 7 | 7 | |
| 13 | 16 | 15 | 15 | 15 | 16 | 16 | 12 | 8 | 7 | 7 | 8 | 10 | |
| Operating Profit | -3 | -1 | -2 | -3 | -2 | -3 | -5 | -5 | -2 | -3 | 0 | -1 | -3 |
| OPM % | -24.76% | -6.04% | -16.10% | -26.07% | -17.07% | -21.07% | -41.06% | -88.69% | -38.14% | -66.91% | 3.99% | -12.78% | -37.82% |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | |
| Interest | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| Depreciation | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| Profit before Tax | -5 | -4 | -5 | -6 | -5 | -6 | -8 | -8 | -5 | -6 | -3 | -2 | -2 |
| Tax % | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.24% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% |
| Net Profit | -5 | -4 | -5 | -6 | -5 | -6 | -8 | -8 | -5 | -6 | -3 | -2 | -2 |
| -2.47 | -1.66 | -2.31 | -2.71 | -2.40 | -2.67 | -3.59 | -3.83 | -2.47 | -2.85 | -1.45 | -1.09 | -1.15 |
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 4 | 34 | 48 | 33 | 54 | 60 | 52 | 50 | 43 | 25 | |
| 14 | 12 | 41 | 58 | 52 | 71 | 94 | 68 | 59 | 58 | 31 | |
| Operating Profit | -12 | -8 | -8 | -10 | -19 | -18 | -34 | -16 | -9 | -15 | -6 |
| OPM % | -961.72% | -226.62% | -22.21% | -20.44% | -55.53% | -32.73% | -56.94% | -30.27% | -17.30% | -34.70% | -23.82% |
| 1 | -0 | -1 | 0 | 0 | 1 | 1 | 1 | 0 | 1 | 2 | |
| Interest | 1 | 3 | 5 | 6 | 6 | 6 | 5 | 3 | 5 | 6 | 7 |
| Depreciation | 4 | 4 | 4 | 4 | 5 | 5 | 6 | 7 | 7 | 7 | 6 |
| Profit before Tax | -16 | -16 | -18 | -20 | -29 | -28 | -45 | -25 | -20 | -27 | -14 |
| Tax % | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.06% | -0.00% |
| Net Profit | -16 | -16 | -18 | -20 | -29 | -28 | -45 | -25 | -20 | -27 | -14 |
| EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -14.37 | -20.81 | -11.30 | -9.15 | -12.49 | — |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
COMPOUNDED SALES GROWTH
- 10 Years:
- —
- 5 Years:
- 5%
- 3 Years:
- -10%
COMPOUNDED PROFIT GROWTH
- 10 Years:
- —
- 5 Years:
- —
- 3 Years:
- —
STOCK PRICE CAGR
- 10 Years:
- -6%
- 5 Years:
- -19%
- 3 Years:
- -5%
- 1 Year:
- -21%
RETURN ON EQUITY
- 10 Years:
- -98%
- 5 Years:
- 0%
- 3 Years:
- 0%
- Last Year:
- 0%
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 13 | 14 | 14 | 17 | 18 | 20 | 22 | 22 | 22 | 22 |
| -4 | -12 | -32 | -31 | -51 | -67 | -97 | -121 | -141 | -168 | |
| 74 | 90 | 101 | 100 | 113 | 161 | 194 | 233 | 242 | 260 | |
| Trade Payables | 12 | 11 | 18 | 21 | 23 | 21 | 38 | 15 | 19 | 18 |
| 20 | 20 | 25 | 36 | 31 | 24 | 33 | 26 | 36 | 37 | |
| Total Liabilities | 116 | 122 | 126 | 142 | 134 | 159 | 190 | 175 | 178 | 169 |
| 93 | 102 | 101 | 101 | 105 | 118 | 139 | 147 | 150 | 146 | |
| Capital Work in Progress | 11 | 4 | 2 | 2 | 2 | 10 | 7 | 2 | 0 | 1 |
| 6 | 5 | 12 | 9 | 15 | 17 | 26 | 12 | 10 | 6 | |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | |
| Cash & Bank | 0 | 0 | 0 | 17 | 0 | 1 | 0 | 0 | 0 | 0 |
| 7 | 11 | 11 | 13 | 11 | 14 | 19 | 13 | 16 | 16 | |
| Total Assets | 116 | 122 | 126 | 142 | 134 | 159 | 190 | 175 | 178 | 169 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| -15 | -8 | -1 | 4 | -35 | -15 | -17 | -25 | 2 | -8 | |
| Cash from Investing | -4 | -5 | -3 | -4 | -10 | -23 | -23 | -13 | -8 | -5 |
| Cash from Financing | 13 | 16 | 9 | 17 | 29 | 38 | 40 | 37 | 6 | 13 |
| -6 | -0 | 0 | 17 | -17 | 1 | -1 | -0 | 0 | 0 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| PER SHARE | ||||||||||
| EPS (₹) | -12.49 | -11.68 | -12.97 | -12.03 | -16.04 | -14.45 | -20.65 | -11.45 | -9.15 | -12.49 |
| Book Value (₹) | 7.15 | 1.07 | -12.94 | -8.59 | -18.14 | -23.91 | -34.83 | -46.13 | -55.29 | -67.83 |
| Dividend per Share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash EPS (₹) | -8.75 | -8.30 | -9.61 | -9.39 | -13.44 | -11.84 | -17.73 | -8.41 | -6.01 | -9.39 |
| PROFITABILITY | ||||||||||
| Operating Margin % | -806.82% | -224.49% | -21.60% | -19.75% | -54.44% | -31.57% | -55.00% | -29.08% | -17.30% | -34.70% |
| Net Margin % | -1157.81% | -454.63% | -52.77% | -41.90% | -86.41% | -52.81% | -74.58% | -47.36% | -39.13% | -62.20% |
| ROE % | -683.34% | -296.70% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| ROCE % | -25.38% | -27.13% | -28.95% | -35.41% | -56.96% | -40.28% | -57.38% | -28.59% | -18.99% | -29.92% |
| -14.60% | -13.46% | -14.38% | -14.92% | -20.91% | -19.36% | -25.51% | -13.54% | -11.17% | -15.52% | |
| EFFICIENCY | ||||||||||
| Debtor Days | 52 | 84 | 10 | 12 | 17 | 2 | 4 | 5 | 9 | 8 |
| Inventory Days | 1436 | 573 | 93 | 79 | 131 | 107 | 129 | 131 | 79 | 67 |
| Payable Days | 0 | 3559 | 414 | 310 | 507 | 305 | 264 | 378 | 949 | 1219 |
| 1487 | -2902 | -311 | -218 | -359 | -196 | -131 | -242 | -861 | -1145 | |
| FINANCIAL HEALTH | ||||||||||
| Debt to Equity (x) | 3.27x | 32.19x | -3.16x | -3.74x | -2.03x | -2.37x | -1.91x | -1.84x | -1.62x | -1.45x |
| Interest Coverage (x) | -21.09x | -3.60x | -2.45x | -2.18x | -3.81x | -3.52x | -7.26x | -7.30x | -3.21x | -3.55x |
| 0.32x | 0.41x | 0.41x | 0.56x | 0.44x | 0.44x | 0.45x | 0.33x | 0.28x | 0.10x | |
| GROWTH | ||||||||||
| Revenue Growth % | 0.00% | 173.74% | 856.86% | 41.38% | -30.04% | 60.72% | 11.18% | -12.68% | -3.29% | -14.10% |
| Operating Profit Growth % | -132.51% | 30.32% | 7.94% | -29.29% | -92.84% | 6.79% | -93.68% | 53.83% | 45.43% | -73.11% |
| Net Profit Growth % | -108.17% | 1.66% | -11.06% | -12.27% | -44.28% | 1.78% | -57.01% | 44.55% | 20.10% | -36.55% |
| 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 20.10% | -36.55% | |
| VALUATION | ||||||||||
| P/E (x) | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x |
| P/B (x) | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | -1.10x | -0.98x |
| Dividend Yield % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | -39.30x | -24.86x |
Documents
Corporate disclosures, annual reports, credit ratings, and concall transcripts
2026-09-04 - Krebs Biochemicals and Industries Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on September 29, 2026
2026-09-03 - Krebs Biochemicals and Industries Limited has informed the Exchange about Copy of Newspaper Publication w.r.t. prior intimation of 34th AGM of the Company.
2026-08-07 - Krebs Biochemicals and Industries Limited has informed the Exchange about Copy of Newspaper Publication
2026-08-06 - Krebs Biochemicals and Industries Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.
2026-07-02 - Krebs Biochemicals and Industries Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018
2026-06-26 - Krebs Biochemicals and Industries Limited has informed the Exchange about Scheme of Arrangement
2026-06-26 - Outcome of Board MEETING
2026-06-22 - Krebs Biochemicals and Industries Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
2026-05-22 - Krebs Biochemicals and Industries Limited has informed the Exchange about Copy of Newspaper Publication
News
Recent coverage and analyst commentary for KREBSBIO
Loading news…
AI Stock Analyst
Krebs Biochemicals & Industries Ltd.
Sign in to Chat with AI
Log in with your 5nance account to ask institutional questions about performance, financials, and outlook.
✨ Sign In to ChatFree 5nance Account